🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

HematoCare: Feasibility of a Survivorship Care Plan for Hematologic Cancer Patients Undergoing HSCT

RecruitingNAAges 18 Years - anyAllAzienda USL Reggio Emilia - IRCCS
NCT07579065 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a feasibility study to implement a Survivorship Care (SC) Plan for patients with hematologic cancer undergoing hematopoietic stem cell transplantation (HSCT). The study evaluates if the intervention is feasible within the Italian national health system, focusing on retention rates, quality of life, unmet needs and caregiver burden

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with hematologic cancer candidates for HSCT (autologous or allogeneic) and their informal caregivers * Able to provide informed consent * Able to communicate in Italian Exclusion Criteria: * Patients or caregivers with comorbidities hindering participation (e.g., significant cognitive limitations)
💊

What it tests

  • Survivorship Care (SC) Plan
📍

Where

1 site
Research and EBP Unit, Azienda USL-IRCCS di Reggio Emilia
Reggio Emilia, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy